Results 31 to 40 of about 9,189 (185)

Assessment of broth disk elution method for aztreonam in combination with ceftazidime/avibactam against Enterobacterales isolates

Microbiology Spectrum
The combination of aztreonam with ceftazidime/avibactam is considered a potential therapeutic approach for the treatment of infections caused by metallo-β-lactamase (MBL)-producing isolates.
Peipei Song, Jian Xu, Lan Jiang, Qin Zhang, Chenggui Liu   +4 more
doaj   +2 more sources

Antimicrobial susceptibility of enterobacterales causing bloodstream infection in United States medical centres: comparison of aztreonam-avibactam with beta-lactams active against carbapenem-resistant enterobacterales

BMC Infectious Diseases
Background Bloodstream infection (BSI) is associated with poor outcomes especially when effective antimicrobial therapy and control of infection source are delayed.
Helio S. Sader, John H. Kimbrough, Rodrigo E. Mendes, Mariana Castanheira   +3 more
doaj   +2 more sources

Efficacy of aztreonam/avibactam against Stenotrophomonas maltophilia alone and in combination with tigecycline

İstanbul Journal of Pharmacy
Background and Aims: Stenotrophomonas maltophilia is a multidrug-resistant opportunistic pathogen that threatens human and public health because of its widespread intrinsic and acquired antibiotic resistance.
Özlem Oyardı, Gülbeyaz Altunboğa, Fatıma Yılmaz, Zayre Erturan   +3 more
openaire   +2 more sources

In Vitro Activities of Aztreonam-avibactam and Comparator Agents against Metallo-β-lactamase-producing Enterobacterales Collected in the Middle East and Africa, ATLAS Global Surveillance Program, 2018-2022

International Journal of Infectious Diseases
Background: Aztreonam-avibactam is a β-lactam/β-lactamase inhibitor combination being developed for use against carbapenem-resistant Enterobacterales (CRE), particularly those carrying metallo-β-lactamases (MBLs).
Dr Mark Estabrook, Dr Gregory Stone, Dr Daniel Sahm   +2 more
doaj   +2 more sources

Aztreonam Combinations with Avibactam, Relebactam, and Vaborbactam as Treatment for New Delhi Metallo-β-Lactamase-Producing Enterobacterales Infections—In Vitro Susceptibility Testing

Pharmaceuticals
Antimicrobial resistance is a major global health issue. Metallo-β-lactamases (MBL), in particular, are problematic because they can inactivate all classes of β-lactams except aztreonam.
Małgorzata Brauncajs, Filip Bielec, Marlena Malinowska, Dorota Pastuszak-Lewandoska   +3 more
doaj   +2 more sources

Reducing aztreonam/avibactam waste: insights from Monte Carlo simulations

Journal of Antimicrobial Chemotherapy
Abstract Background The fixed-dose combination of aztreonam/avibactam is administered with a loading dose (LD), resulting in systematic drug wastage in patients with preserved renal function. Whether the LD can be reduced remains unclear.
Fromage, Yeleen, Sayadi, Hamza, Labriffe, Marc, Monchaud, Caroline, Codde, Cyrielle, Woillard, Jean-Baptiste   +5 more
openaire   +4 more sources

In vitro activity of aztreonam–avibactam against metallo-β-lactamase-producing Enterobacteriaceae—A multicenter study in China [PDF]

International Journal of Infectious Diseases, 2020
Objectives: To study the molecular epidemiology of clinical metallo-β-lactamase (MBL)-producing Enterobacteriaceae isolates in China and to evaluate the antimicrobial susceptibility of MBL-Enterobacteriaceae isolates to aztreonam–avibactam.
Biying Zhang, Zhichen Zhu, Wei Jia, Fen Qu, Bin Huang, Bin Shan, Hua Yu, Yiwei Tang, Liang Chen, Hong Du   +9 more
doaj   +3 more sources

In Vitro Activity of Aztreonam-avibactam and Comparator Agents Against Carbapenemase-producing Enterobacterales Collected in Turkey and the Middle East as Part of the ATLAS Surveillance Program: 2018-2022

Journal of Global Antimicrobial Resistance
BACKGROUND: Aztreonam-avibactam is approved in the European Union for treatment of hospital/ventilator acquired bacterial pneumonia, complicated intraabdominal infection, complicated urinary tract infection and infections where treatment options are ...
Mark Estabrook, Meredith Hackel, Gregory Stone, Katherine Perez, Daniel Sahm   +4 more
doaj   +2 more sources

Whole-genome analysis of NDM-producing Providencia hangzhouensis associated with recurrent bacteraemia with rapid development of aztreonam-avibactam resistance [PDF]

Emerging Microbes and Infections
A 60-year-old male with recurrent bacteremia associated with necrotizing pancreatitis was followed over 17 months, during which six clinical isolates of Providencia were obtained. The index isolate (R1) was susceptible to aztreonam-avibactam (MIC 4 mg/L),
Ka Lip Chew, Yuan Qiao, Priscillia Lye, Joey Cruz Cabang, Nur Aisyah Binte Abu Bakar, Ker Xin Tan, Jeanette Teo   +6 more
doaj   +2 more sources

Activity of Aztreonam/Avibactam and Recently Approved β-Lactamase Inhibitor Combinations against Enterobacterales and Pseudomonas aeruginosa from Intensive Care Unit and Non-Intensive Care Unit Patients

Antibiotics
We evaluated the activities of aztreonam/avibactam and recently approved β-lactamase inhibitor combinations (BLICs) to compare the antimicrobial susceptibility patterns of Enterobacterales and Pseudomonas aeruginosa isolated from intensive care unit (ICU)
Helio S. Sader, Rodrigo E. Mendes, John H. Kimbrough, Cory M. Hubler, Mariana Castanheira   +4 more
doaj   +2 more sources